Overview of ifosfamide in small cell lung cancer.

  title={Overview of ifosfamide in small cell lung cancer.},
  author={David S. Ettinger},
  journal={Seminars in oncology},
  volume={19 1 Suppl 1},
Ifosfamide, an analogue of the alkylating agent cyclophosphamide, is one of the most active agents in the treatment of small cell lung cancer (SCLC). As a single agent, the drug produces a greater than 50% objective response rate. Recent studies using ifosfamide in combination with other active agents, ie, cisplatin, carboplatin, and etoposide, In the… CONTINUE READING